New stroke drug in trials

BMJ 2001; 322 doi: (Published 07 April 2001) Cite this as: BMJ 2001;322:818
  1. Abi Berger
  1. BMJ

    A new drug that limits brain damage after a stroke has entered large scale (phase III) clinical trials which, if successful, could lead to its being licensed. The drug, made by Bristol-Myers Squibb in the United States, has been designed to prevent the cell death that tends to follow an ischaemic episode (Nature Medicine 2001;7:471-7).

    Soon after an ischaemic stroke occurs, the core area of the brain immediately around the occluded blood vessel loses most of its oxygen supply and …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription